Trials / Recruiting

RecruitingNCT06241846

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

A Multicenter, Open-Label, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 100 (estimated)

Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. · Industry
Sex: Male
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

Type	Name	Description
DRUG	YL201 for Injection	Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks on Day 1 or twice every 3 weeks on Day 1 and Day 8 during a 3-week (21-day) cycle.

Timeline

Start date: 2024-02-22
Primary completion: 2027-02-01
Completion: 2029-02-01
First posted: 2024-02-05
Last updated: 2025-08-27

Locations

24 sites across 1 country: China

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06241846. Inclusion in this directory is not an endorsement.